The Prescriber’s Role in Access

The prescriber sits at the centre of every legal cannabis access story in Australia

Roughly 700,000 approvals had been issued under Australia's medicinal cannabis access pathways by early 2024 , a number the TGA publishes quarterly and one that still surprises people who assume the system is barely functional. It isn't barely functional. It's actually reasonably well-worn by now, though the rules governing who can prescribe, under what authority, and with what ongoing obligations, remain genuinely complex. This article is about those rules: not about any particular product, not about whether cannabis is right for any particular patient, but about the regulatory architecture that sits around the prescriber.

I'll admit I spent the better part of a wet Canberra Tuesday once cross-referencing the Therapeutic Goods (Poisons Standard , Cannabis and Cannabis Resin) Order 2016 against the current Poisons Standard schedule entries. It's the kind of thing I do. Trevor the sourdough starter was, as usual, more predictable.

Schedule status: where everything starts

The first thing to understand is that "medicinal cannabis" is not a single scheduling category. The cannabinoid profile and THC concentration of a product determine which schedule of the Poisons Standard applies.

Low-dose cannabidiol (CBD) products meeting specific concentration thresholds sit at Schedule 4 (Prescription Only). That means a registered medical or nurse practitioner can prescribe them under the same framework that applies to most other prescription medicines, and in some jurisdictions pharmacists can supply certain Schedule 4 CBD products without a prescription under a pharmacist-only exemption introduced in 2021.

Products containing tetrahydrocannabinol (THC) above threshold concentrations are Schedule 8 (Controlled Drug). That is the same schedule as morphine and oxycodone. The prescribing rules are correspondingly stricter: state and territory controlled-drug authorities typically require permits, prescriptions must be written to specific standards, and quantities dispensed are monitored. Prescribers need to be across both the federal scheduling framework and their own jurisdiction's controlled-drug legislation simultaneously. It's a two-layer system, and that second layer varies by state.

The two federal access pathways

Below the scheduling layer sit the two main federal mechanisms through which unapproved medicinal cannabis products reach patients: the Special Access Scheme (SAS) and the Authorised Prescriber (AP) pathway.

Most prescriptions in Australia flow through SAS Category B. Under this pathway, a registered medical practitioner, nurse practitioner, or (for certain categories) a dentist or optometrist applies to the TGA for approval to supply a specific unapproved product to a named individual patient. The application is made online. The TGA assesses it, typically within a few days for straightforward cases. If approved, that approval is patient-specific and product-specific , it does not extend to other patients or other products. The prescriber then writes the prescription under the relevant state controlled-drug or prescription framework. Each new patient, each new product iteration, means a new SAS B application.

The Authorised Prescriber pathway works differently. A practitioner applies to the TGA; supported by an ethics committee endorsement or, since regulatory changes in 2020, an endorsement from a TGA-approved specialist college, to be authorised to prescribe a specified unapproved product or class of product to a class of patients, without seeking individual approval for each one. Once authorised, they report to the TGA every six months on the number of patients they've supplied. The AP designation sits with the individual prescriber and for defined circumstances; it doesn't grant open-ended prescribing rights across all products.

In practice, SAS B handles the volume. The AP pathway is more commonly used by specialists who are seeing high numbers of patients with similar presentations. Both pathways require the product to meet TGA requirements including Good Manufacturing Practice (GMP) standards, either Australian GMP or a comparable overseas standard recognised by the TGA. Products that have full ARTG registration (a small but growing list) can be prescribed like any registered medicine, without SAS or AP approval, though they still attract the scheduling rules.

What the prescriber is actually responsible for

This is where I think public understanding tends to have a gap. An approval from the TGA under SAS B is not a rubber stamp on clinical appropriateness. The TGA's role in SAS B is to confirm the access pathway is being used correctly and that the product meets supply requirements; it is not a second clinical opinion. Clinical judgement sits entirely with the prescriber. They are responsible for the patient assessment, for determining whether a cannabis-based medicine is appropriate for that patient's circumstances, for monitoring, for ongoing review, and for all standard prescribing obligations under their medical board registration.

The Medical Board of Australia's Good Medical Practice guidelines apply. The prescriber must keep records. They must counsel the patient, including on impairment risks (driving laws in most Australian states create obligations here, since THC impairment is assessed independently of medical authorisation). For Schedule 8 products, state controlled-drug permit conditions typically impose additional record-keeping and prescribing volume requirements.

Honestly, the regulatory weight on the prescriber is substantial, which is part of why not every GP has engaged with the pathway. That's neither a criticism nor a recommendation, it's just what the framework looks like when you read the obligations closely.

Nurse practitioners and the expanding prescriber pool

Since 2020, nurse practitioners have been able to prescribe through SAS B and, in certain circumstances, apply for AP status for Schedule 4 cannabis medicines. This was a meaningful expansion of the prescriber pool, particularly for regional and remote patients where GP access is constrained. The conditions are that the nurse practitioner must be prescribing within their scope of practice and, for Schedule 8 products, the state/territory controlled-drug framework still needs to permit nurse practitioner prescribing, and not all of them do uniformly. So the federal expansion doesn't map neatly onto every jurisdiction. That's a genuine structural tension in the system that hasn't been fully resolved.

Products, formulations, and what prescribers are choosing from

Prescribers selecting a product are working from a catalogue of unapproved goods that are not individually evaluated for efficacy by the TGA in the way ARTG-registered medicines are. GMP certification covers manufacturing quality; it confirms the product contains what it says it contains, at consistent concentrations, but it isn't a therapeutic efficacy assessment. Prescribers who engage seriously with this space tend to develop familiarity with product types: oils and capsules (where first-pass metabolism affects how cannabinoids are absorbed), and bioavailability varies considerably between routes of administration.

Formulations range from single-cannabinoid isolates to broad-spectrum and full-spectrum preparations, the latter retaining a broader range of cannabinoids and terpenes. Whether the composition of a preparation matters clinically is a research question; prescribers draw on the available evidence, which for many cannabinoid formulations remains limited and methodologically heterogeneous.

A note on the low-dose CBD pharmacist pathway

For completeness: since February 2021, Schedule 3 (Pharmacist Only) status has applied to certain low-dose CBD products that meet the TGA's specific criteria. This means a pharmacist can supply them without a prescription, following assessment of the patient. No doctor is required. The products must be specifically listed, meet the relevant concentration and dose thresholds, and the pharmacist conducts their own professional assessment. At time of writing, the practical uptake of this pathway has been limited because few products have actually received the relevant ARTG entry at Schedule 3 concentration. The pathway exists; the product supply through it is thin. That gap between regulatory architecture and commercial reality is, in my view, one of the more underreported features of the whole framework.

Sources

• Medicinal Cannabis Access Pathways, Therapeutic Goods Administration (TGA)
• Access to Medicinal Cannabis Products in Australia: Data Summary; TGA
• Medicinal Cannabis, Australian Government Department of Health and Aged Care
• Medicinal Cannabis in Australia: The Missing Evidence, NCBI / PubMed Central

, Marcus Hale, Regulatory researcher; TGA & access law